Mordern treatment of myelodysplastic syndrome / 中国实用内科杂志

Myelodysplastic syndrome (MDS) is a clonal disorders characterized by ineffective hematopoiesis,which can lead to either fatal cytopenias or acute myelogenous leukemias (AML).MDS mainly occurs in the elderly population.The current use of allogeneic hematopoietic stem cell transplantation for MDS patients is the only medical care,but not available for patients who are above 60 years.Recently,several new biological and chemotherapeutic agents have been used in the treatment of MDS alone or jointlly,which may result in the improvement of hematologic parameters and the prevention of disease progression.